TriangleNCT01408563 · OUTCOME
1 Year Relapse Rate
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 1 year
What was measured
The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.
Groups in this outcome
Fludarabine/Melphalan/TBI
All patients receive same therapy Fludarabine: 30 mg/m2/day IV x 6 days Melphalan: 100 mg/m2/day IV x 1 day Total Body Radiation: 200 cGy on Day 0 Cord Blood: 2 cord blood units IV
| Group | Source count |
|---|---|
| Fludarabine/Melphalan/TBI | 31 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Fludarabine/Melphalan/TBI | 20 | Not reported | 4 | 27.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4
- upper Limit
- 27.3
- value
- 20
- denoms
- counts
- group Id
- OG000
- value
- 31
- units
- Participants
- description
- The percentage of participants that relapsed within 12 months. Relapse is defined by either morphological or cytogenetic evidence of the original malignancy consistent with pre-transplant features.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- All patients receive same therapy Fludarabine: 30 mg/m2/day IV x 6 days Melphalan: 100 mg/m2/day IV x 1 day Total Body Radiation: 200 cGy on Day 0 Cord Blood: 2 cord blood units IV
- id
- OG000
- title
- Fludarabine/Melphalan/TBI
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- 1 Year Relapse Rate
- type
- SECONDARY
- unit Of Measure
- percentage
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice